ScholarIQanswers from OpenAlex & ORCID
Sumanta K. Pal
ResearcherPublications, citations & collaboration network
Sumanta K. Pal is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sumanta K. Pal have?
ScholarIQindexed works
Sumanta K. Pal has 1,401 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sumanta K. Pal have?
ScholarIQcitation count
Sumanta K. Pal has 34,411 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sumanta K. Pal?
ScholarIQh-index
Sumanta K. Pal has an h-index of 89 in OpenAlex.
What is the i10-index of Sumanta K. Pal?
ScholarIQi10-index
Sumanta K. Pal has an i10-index of 461 in OpenAlex.
What is the ORCID of Sumanta K. Pal?
ScholarIQorcid
The ORCID for Sumanta K. Pal is on the source record.
What is the OpenAlex record for Sumanta K. Pal?
ScholarIQopenalex
The OpenAlex for Sumanta K. Pal is on the source record.
What are the most-cited papers on Sumanta K. Pal?
ScholarIQmost cited works
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
Jenny J. Ko, Wanling Xie, Nils Kroeger, Jae-lyun Lee, Brian I. Rini, Jennifer J. Knox, Georg A. Bjarnason, Sandy Srinivas, Sumanta K. Pal, Takeshi Yuasa, Martin Smoragiewicz, Frede Donskov, Ravindran Kanesvaran, Lori Wood, D. Scott Ernst, Neeraj Agarwal, Ulka N. Vaishampayan, Sun Young Rha, Toni K. Choueiri, Daniel Y.C. Heng
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
Shaan Dudani, Guillermo de Velasco, J. Connor Wells, Chun Loo Gan, Frede Donskov, Camillo Porta, Anna Paola Fraccon, Felice Pasini, Jae‐Lyun Lee, Aaron R. Hansen, Georg A. Bjarnason, Benoit Beuselinck, Sumanta K. Pal, Takeshi Yuasa, Nils Kroeger, Ravindran Kanesvaran, M. Neil Reaume, Christina Canil, Toni K. Choueiri, Daniel Y.C. Heng
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah M. Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff M. Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker‐Radtke, Guru Sonpavde, Jonathan D. Tward, Geoffrey Wile, Mary A. Dwyer, Lisa A. Gurski
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Sumanta K. Pal, Laurence Albigès, Piotr Tomczak, Cristina Suárez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi, Friedemann Zengerling, Chan Kim, Takahiro Osawa, Martín Ángel, Suyasha Gupta, Omara Khan, Guillaume Bergthold, Bo Liu, Melania Kalaitzidou, Mahrukh Huseni, Christian Scheffold, Thomas Powles, Toni K. Choueiri